NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Grifols SA GRFS
10 fiscal years on record · EUR · FY2024 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
EUR 7.2B
Revenue, FY2024 · full 10-year series below
Revenue €B
Net income €B
FY2024 · Revenue 7.2 · Net income 0.2
3B6B
2015201820212024
Compound annual growth
Revenue compounded at +7.2% a year over the five years to FY2024.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
3 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2024 · Operating 16.5% · Net 3.0%
10%20%
201520192024
ROE
FY2024 · ROE 2.8%
5%10%15%
201520192024
Three returns, three denominators.
Each EUR of equity produced 3 cents of profit this year.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · EUR
row low → row highnegative—not applicable◌not available in our data
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue €B | 7.2 | 6.6 | 6.1 | 4.9 | 5.3 | 5.1 | 4.5 | 4.3 | 4.0 | 3.9 |
| Operating income €B | 1.2 | 0.8 | 0.8 | 0.6 | 1.0 | 1.1 | 1.0 | 1.0 | 0.9 | 1.0 |
| EBITDA €B | 1.6 | 1.2 | 1.2 | 1.0 | 1.3 | 1.4 | 1.2 | 1.2 | 1.1 | 1.2 |
| Income tax €B | 0.2 | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.0 | 0.2 | 0.2 |
| Net income €B | 0.2 | 0.0 | 0.2 | 0.2 | 0.6 | 0.6 | 0.6 | 0.7 | 0.5 | 0.5 |
| Free cash flow €B | 0.7 | −0.0 | −0.3 | 0.3 | 0.8 | 0.3 | 0.5 | 0.6 | 0.3 | 0.2 |
| EPS, diluted € | 0.23 | 0.06 | 0.27 | 0.28 | 0.90 | 0.91 | 0.87 | 0.97 | 0.80 | 0.78 |
| Dividend / sh € | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % | 1 | 0 | 0 | 137 | 18 | 38 | 23 | 19 | 23 | — |
| ROE % | 2.8 | 0.8 | 3.3 | 3.6 | 12.5 | 13.8 | 15.2 | 18.0 | 15.5 | 16.1 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Compare
This company against its peers
Grifols SAvsSanofiSame industry: Pharmaceutical PreparationsGrifols SAvsLakefront Biotherapeutics NVSame industry: Pharmaceutical PreparationsGrifols SAvsEvotec SESame industry: Pharmaceutical PreparationsGrifols SAvsAscendis Pharma A/SSame industry: Pharmaceutical PreparationsGrifols SAvsNanobiotix S.a.Same industry: Pharmaceutical PreparationsGrifols SAvsProQR Therapeutics N.v.Same industry: Pharmaceutical PreparationsGrifols SAvsInventiva S.a.Same industry: Pharmaceutical Preparations
Provenance
Company facts, as filed
How we verify · 0 failures in 49 reconciliationsAUDITED
Reconciled in 10 of the 10 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Eight checks were skipped: EPS is not tagged before 2015. Eight checks were skipped: revenue is not tagged before 2015.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsnot stated in the filings
Data on record since2015